DE68921918T2 - Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. - Google Patents

Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.

Info

Publication number
DE68921918T2
DE68921918T2 DE68921918T DE68921918T DE68921918T2 DE 68921918 T2 DE68921918 T2 DE 68921918T2 DE 68921918 T DE68921918 T DE 68921918T DE 68921918 T DE68921918 T DE 68921918T DE 68921918 T2 DE68921918 T2 DE 68921918T2
Authority
DE
Germany
Prior art keywords
effectiveness
individual patients
predicting
procedure
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921918T
Other languages
English (en)
Other versions
DE68921918D1 (de
Inventor
Alan M Gewirtz
Bruno Calabretta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of DE68921918D1 publication Critical patent/DE68921918D1/de
Application granted granted Critical
Publication of DE68921918T2 publication Critical patent/DE68921918T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE68921918T 1988-05-09 1989-05-04 Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. Expired - Fee Related DE68921918T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19144988A 1988-05-09 1988-05-09

Publications (2)

Publication Number Publication Date
DE68921918D1 DE68921918D1 (de) 1995-05-04
DE68921918T2 true DE68921918T2 (de) 1995-09-07

Family

ID=22705545

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921918T Expired - Fee Related DE68921918T2 (de) 1988-05-09 1989-05-04 Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.

Country Status (5)

Country Link
US (1) US5427916A (de)
EP (1) EP0341904B1 (de)
JP (1) JPH0636759B2 (de)
AT (1) ATE120497T1 (de)
DE (1) DE68921918T2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930703462A (ko) * 1990-09-24 1993-11-30 로저 브렌트 검색 분석 방법
ES2092056T3 (es) * 1991-09-23 1996-11-16 Pfizer Procedimiento para detectar arnm y adn especificos en celulas.
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
JPH07507926A (ja) * 1992-06-16 1995-09-07 ホイツテイアー・インステイテユート・フオー・ダイアビテイーズ・アンド・エンドクリノロジー サポリン含有タンパク質の組換え産生
DK0646182T3 (da) * 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
GB9220777D0 (en) * 1992-10-02 1992-11-18 Univ Leicester Oligonucleotide probes
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
ATE423852T1 (de) 1996-04-05 2009-03-15 Antonio Giordano Methoden zur diagnose und prognose von krebs
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
WO2001023615A1 (en) * 1999-09-29 2001-04-05 Lifespan Biosciences, Inc. Anti-aging nucleic acid and protein targets
WO2002039121A2 (en) * 2000-11-03 2002-05-16 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US7012200B2 (en) * 2004-02-13 2006-03-14 Sonion Roskilde A/S Integrated volume control and switch assembly
WO2005112924A2 (en) * 2004-04-27 2005-12-01 California Institute Of Technology Methods of treating cancer by inhibiting histone gene expression
JP2008503206A (ja) * 2004-05-25 2008-02-07 日立化成工業株式会社 癌感受性を測定する方法
US20090011410A1 (en) * 2004-10-20 2009-01-08 Masato Mitsuhashi Method for tailoring administration of drugs by quantitation of mrna
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
WO2006116721A1 (en) * 2005-04-28 2006-11-02 Hitachi Chemical Research Center, Inc. Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements
EP1907855A4 (de) * 2005-07-12 2009-11-11 Univ Temple Genetische und epigenetische änderungen bei der diagnose und behandlung von krebs
EP1937280B1 (de) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Zusammensetzungen zur Therapie von Bcl2-assoziierten Tumoren
EP2591794A1 (de) 2006-01-05 2013-05-15 The Ohio State University Research Foundation Anomalien bei Mikro-RNA-Expressionen in endokrinen und azinösen Pankreastumoren
ES2536423T3 (es) 2006-01-05 2015-05-25 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico de cáncer de próstata
ES2429404T3 (es) 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
EP2522746B1 (de) 2006-03-02 2014-11-12 The Ohio State University Research Foundation Mikro-RNA-Expressionsprofil im Zusammenhang mit Bauchspeicheldrüsenkrebs
EP1996731A2 (de) 2006-03-20 2008-12-03 The Ohio State University Research Foundation Mikrorna-fingerabdrücke während humaner megakaryozytopoiese
US20090298071A1 (en) * 2006-05-08 2009-12-03 Masato Mitsuhashi Method for testing drug sensitivity in solid tumors by quantifying mrna expression in thinly-sliced tumor tissue
WO2007134142A2 (en) * 2006-05-11 2007-11-22 University College Dublin Methods and compositions for identifying and using p21-regulated proteins
AU2007272947B2 (en) 2006-07-13 2013-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Micro-RNA-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8841436B2 (en) * 2007-03-15 2014-09-23 University Hospitals Cleveland Medical Center Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
CN101711287B (zh) 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2650383A1 (de) 2007-08-03 2013-10-16 The Ohio State University Research Foundation Ultrakonservierte Bereiche zur Codierung von ncRNA
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
JP5401460B2 (ja) 2007-09-06 2014-01-29 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト卵巣癌中のマイクロｒｎａシグネチャー
JP5723156B2 (ja) 2007-10-11 2015-05-27 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 食道腺癌の診断及び治療のための方法及び組成物
CN101855367A (zh) * 2007-11-14 2010-10-06 日立化成工业株式会社 外周血白细胞中FC受体介导的肿瘤坏死因子超家族mRNA表达
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
WO2010149666A1 (en) 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
WO2011023413A1 (en) 2009-08-31 2011-03-03 Alcedo Biotech Gmbh Microrna-based methods and compositions for reprogramming cells
US20120238488A1 (en) 2009-09-08 2012-09-20 Konstantinos Alevizopoulos Compounds and methods for treating neoplasia
WO2011109637A1 (en) 2010-03-03 2011-09-09 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US20130303500A1 (en) 2010-07-30 2013-11-14 Medexis S.A. Compounds and methods for treating neoplasia
WO2012025633A1 (en) 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
EP2971129B1 (de) 2013-03-15 2018-05-09 Sutter Bay Hospitals Falz zur verwendung als target für therapien zur behandlung von krebs
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI76119C (fi) * 1986-02-27 1988-09-09 Orion Yhtymae Oy Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
EP0290144A1 (de) * 1987-05-05 1988-11-09 City of Hope Verfahren zum Nachweis von beginnender Widerstandsfähigkeit gegen therapeutische Agenzien bei Krebskranken

Also Published As

Publication number Publication date
JPH0213400A (ja) 1990-01-17
DE68921918D1 (de) 1995-05-04
JPH0636759B2 (ja) 1994-05-18
US5427916A (en) 1995-06-27
ATE120497T1 (de) 1995-04-15
EP0341904B1 (de) 1995-03-29
EP0341904A3 (de) 1991-11-27
EP0341904A2 (de) 1989-11-15

Similar Documents

Publication Publication Date Title
DE68921918D1 (de) Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.
IE46078L (en) Apparatus for treating living tissues and/or cells by¹electromagnetically inducing voltage and current pulses¹within the tissue and/or cells.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE3869490D1 (de) Verfahren zur elektrochemischen behandlung von stoffen.
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
DE3782917D1 (de) Verfahren zum herabsetzen des gehalts an rueckstaendigen aldehyden in implantierbaren bioprosthetischen geweben.
ATE109514T1 (de) Die verwendung von ausgewählten amphiphilen copolymeren in der behandlung von leder.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
PH25590A (en) Active specific immune suppression
DE3880118D1 (de) Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung.
DE3874019D1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
DE3785602D1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
ES2110091T3 (es) Terapia tumoricida de efecto de alerta.
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
NO882854L (no) Korreksjon med dobbeltraadet rna av avvikende metabolske spor forbundet med ukontrollerte vekstsykluser for tumorceller og virus.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3879754D1 (de) Hydrophiler zusatz zum zuechten von pilzen und verfahren zu seiner verwendung.
DE3884777D1 (de) Verfahren zur Herstellung von Pregneno-Oxazolinen.
FI113153B (fi) Solukasvunsäätelijä
SU649851A1 (ru) Способ искусственного замораживани грунтов
ATE104147T1 (de) Verwendung von inositol-triphosphat zur behandlung von metallvergiftung.
ATE45224T1 (de) Verfahren zur diagnose von a.i.d.s.
NO162739C (no) Fremgangsmaate og innretning for kvantitativ besemmelse avhemoglobinnivaaet i en biologisk proeve.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ES499967A0 (es) Un dispositivo de tratamiento corporal electromagnetico parala modificacion quirurgicamente no invasiva del comporta- miento de desarrollo,reparacion y mantenimiento de celulas ytejidos vivos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee